Chronische Herzinsuffizienz – neue Erkenntnisse

Abstract

Chronic heart failure is one of the most common chronic diseases worldwide with increasing prevalence and incidence. Due to high morbidity and mortality a standardized and evidence-based therapy is crucial. This review presents new pharmacological and interventional developments, as well as new insights due to common comorbidities of patients with chronic heart failure like anemia and hyperkalemia.

Update: Kardiovaskuläre Schlafmedizin

“…Eine Therapie der Herzinsuffizienz, medikamentös oder durch Implantation eines Herzschrittmachers zur kardialen Resynchronisationstherapie, führt zu einer Verbesserung der zentralen, nicht aber der obstruktiven Schlafapnoe [21]. [24,28]).…”

Effects of high-quality nursing care on psychological outcomes in patients with chronic heart failure

“…[1–4] Such disorder often significantly affects quality of life and brings a tremendous burden for both patients’ family and the society. [5–8] It has been estimated that its prevalence was 0.9%, and the mortality was 19.5% annually in China. [9] In addition, the CHF motility was 17.4% in Europe, [10] and 31.4% in United States each year.…”

Depression risk in patients with heart failure in primary care practices in Germany

“…Notwithstanding, depression symptoms are associated with increased risk for HF in a dose response manner. They can trigger extracardiac events which cause HF, such as neurohormonal stress activity, which regulates blood pressure, heart rate, proinflammatory cytokine, and catecholamine levels (Edelmann, 2015; Ewen et al , 2015). Further, depression symptoms influence other risk factors for HF, in particular, obesity and reduced physical activity (Gustad et al , 2014).…”

“…Heart failure (HF) is a condition caused by a number of CVD and is primarily exhibited by the elderly (Uemura, 1988; Peeters et al , 2002; Ramsay et al , 2014). Its prevalence is increasing and an estimated 15 million people in Europe are affected by this disease (Ewen et al , 2015). Epidemiological data show that when considering a steadily aging population and assuming a stable incidence in people over 65 years, a doubling of the incidence of HF is expected compared to the interval 2000 to 2040 (Edelmann, 2015).…”

“…HF is characterized by clinical signs of insufficient cardiac activity such as shortness of breath, fatigue, and fluid retention, an increased incidence of arrhythmias and a reduced quality of life and poor prognosis (Ewen et al , 2015). These impairments can be associated with depression (Heßlinger et al , 2002).…”